Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rocket Doctor AIAIRDF -2.05%32 Cash-to-Debt is 6.62 as of Mar. 2026, which is 57% above its 10-year median of 4.22. GuruFocus rates AIRDF with a GF Score™ of 32/100. The stock has 7 warning signs investors should review. Among 663 Healthcare Providers & Services companies, Rocket Doctor AI ranks better than 77.53% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Rocket Doctor AI's cash to debt ratio for the quarter that ended in Mar. 2026 was 6.62.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Rocket Doctor AIcould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Rocket Doctor AI's Cash-to-Debt or its related term are showing as below:
AIRDF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 4.22 Max: No Debt
Current: 6.62
During the past 7 years, Rocket Doctor AI's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 4.22.
AIRDF's Cash-to-Debt is ranked better than 77.53% of 663
companies
in the Healthcare Providers & Services industry
Industry Median: 0.77
vs AIRDF: 6.62
Rocket Doctor AI (OTCPK:AIRDF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Rocket Doctor AI Cash-to-Debt Related Terms
Rocket Doctor AI Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Rocket Doctor AI's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Health Information Services subindustry, Rocket Doctor AI's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rocket Doctor AI Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Rocket Doctor AI's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Rocket Doctor AI's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rocket Doctor AI (AIRDF) has a Cash-to-Debt of 6.62 as of Mar. 2026. This is 57% above median its historical median of 4.22. According to the industry distribution chart, Rocket Doctor AI ranks #149 out of 663 companies in the Healthcare Providers & Services industry, placing it in the top 22.5%.
Is Rocket Doctor AI's Cash-to-Debt too high?
Rocket Doctor AI's current Cash-to-Debt of 6.62 is 57% above median its 10-year median of 4.22. The Healthcare Providers & Services industry median Cash-to-Debt is 0.77. Rocket Doctor AI's value of 6.62 is 759.7% above this industry median. Based on the distribution chart, Rocket Doctor AI ranks #149 out of 663 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Rocket Doctor AI has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Rocket Doctor AI's Cash-to-Debt compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Rocket Doctor AI ranks #149 out of 663 companies for Cash-to-Debt. This places Rocket Doctor AI in the top 23% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 0.77. Rocket Doctor AI's value of 6.62 is 759.7% above this benchmark. While the company's 10-year median is 4.22 vs. the industry median of 0.77, Rocket Doctor AI has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.77, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rocket Doctor AI's current Cash-to-Debt of 6.62 is 759.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rocket Doctor AI's current Cash-to-Debt is 6.62, which is 57% above median its own 10-year median of 4.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rocket Doctor AI stock overvalued right now?
Rocket Doctor AI (AIRDF) has a current Cash-to-Debt of 6.62. The current Cash-to-Debt is 6.62, which is 57% above median its 10-year median of 4.22 and 759.7% above the Healthcare Providers & Services industry median of 0.77. Rocket Doctor AI's overall GF Score™ is 32/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Rocket Doctor AI (AIRDF), the current Cash-to-Debt is 6.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rocket Doctor AI Inc delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of the company's proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians world-wide. Alongside the GLM and its AI-powered digital health platform and marketplace. The group empowers over 300 MDs to provide care to more than 700,000 patients. Its proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices - improving efficiency, restoring autonomy to MDs, and expanding patient access to care.
32GF Score
Get the complete analysis for AIRDF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIRDF has been successfully added to your 
